Compare AU
Compare MVE vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the S&P Aussie 50 Mid-Caps (MVE) and the BetaShares Global Healthcare ETF - Currency Hedged (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
MVE | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 36 | 63 |
Median incremental investment | $668.99 | $967.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,917.20 | $1,875.72 |
Average age group | > 35 | 26 - 35 |
Key Summary
MVE | DRUG | |
|---|---|---|
Strategy | MVE.AX was created on 2013-10-14 by VanEck. The fund's investment portfolio concentrates primarily on mid cap equity. The Fund is designed to capture the performance of the 50 midcap companies listed on ASX having Market Capitalisation ranking from 51 to 100. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | CAR Group Ltd (4.94 %) Pro Medicus Ltd (4.29 %) REA Group Ltd (4.09 %) | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) |
Top 3 industries | Communication Services (25.45 %) Materials (17.95 %) Information Technology (17.84 %) | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) |
Top 3 countries | Australia (94.11 %) New Zealand (3.28 %) United States (2.61 %) | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) |
Management fee | 0.45 % | 0.57 % |
Key Summary
MVE | DRUG | |
|---|---|---|
Issuer | VanEck | BetaShares |
Tracking index | S&P/ASX Midcap 50 Index - AUD | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.57 % |
Price | $40.80 | $8.12 |
Size | $316.300 million | $191.120 million |
10Y return | 107.32 % | N/A |
Annual distribution yield (5Y) | 3.49 % | 1.90 % |
Market | ASX | ASX |
First listed date | 16/10/2013 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
MVE | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 36 | 63 |
Median incremental investment | $668.99 | $967.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,917.20 | $1,875.72 |
Average age group | > 35 | 26 - 35 |
Pros and Cons
MVE | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
MVE | DRUG |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |